The critical path to medical innovation.
In the United States,the Food and Drug Administration (FDA) and the National Institutes of Health have noted a significant decrease in the number of innovative products reaching patients, in spite of a rapidly expanding basis of fundamental scientific knowledge. A recent FDA report proposes some solutions to this problem.
University of Liverpool, UK. dfw.ce@liverpool.ac.uk
David
D
Williams
D002986:Clinical Trials as Topic / Q000295:instrumentation / Q000379:methods / Q000639:trends; D019091:Critical Pathways / Q000458:organization & administration / Q000639:trends; D018795:Device Approval; D004059:Diffusion of Innovation; D016520:Entrepreneurship / Q000639:trends*; D004867:Equipment Design / Q000379:methods / Q000639:trends; D004864:Equipment and Supplies; D009936:Organizational Innovation; D012106:Research / Q000295:instrumentation* / Q000639:trends*; D012107:Research Design; D035703:Therapies, Investigational / Q000295:instrumentation* / Q000379:methods / Q000639:trends*; D014481:United States; D014486:United States Food and Drug Administration